LDL4 Particle Number

Suppose your cholesterol panel looks fine, but your waistline, blood sugar, or triglycerides don't. In that situation, LDL cholesterol can understate the number of circulating particles that can contribute to plaque. LDL4 particle number describes one part of that particle population. ApoB and total LDL particle number have stronger evidence for assessing the broader burden.

LDL4 is an exploratory marker for risk assessment. The measurement can describe your lipoprotein profile, but there are no universally standardized decision thresholds for this subclass. Choosing treatment around LDL4 hasn't been shown to improve cardiovascular outcomes.

The 2026 ACC/AHA dyslipidemia guideline is explicit here. It rates routine advanced lipoprotein testing, including NMR subclass panels like this one, as Class 3: No Benefit for estimating heart risk or deciding whether to start cholesterol-lowering treatment, and limits it to situations where the result is likely to change treatment. For high triglycerides, diabetes, or other metabolic concerns, the guideline names ApoB as the measurement to add.

What This Number Counts

An LDL particle carries cholesterol through your blood inside a shell of fat and protein. Each particle contains one molecule of apolipoprotein B, usually shortened to ApoB. Routine ApoB testing measures the concentration of that protein, which provides an estimate of the number of circulating particles that can contribute to plaque, including LDL and several other particle types.

This test estimates LDL4 particle concentration in serum using nuclear magnetic resonance spectroscopy, or NMR. Serum is the liquid remaining after blood clots. NMR measures magnetic signals from fats within lipoproteins and uses a calibrated mathematical model to estimate their concentrations. The result is reported in nmol/L.

The method separates LDL into six subclasses. LDL4 is smaller and denser than LDL1 through LDL3, while LDL5 and LDL6 are smaller and denser still. Some research groups LDL3 and LDL4 together as medium-sized LDL; other research groups LDL4 through LDL6 together as small dense LDL. Those broader labels need to be read with the method that produced them.

Your liver releases triglyceride-rich particles called VLDL. As these particles lose triglycerides and undergo other changes in circulation, some become LDL. Insulin resistance can increase the liver's output of triglyceride-rich particles and alter their processing, favoring smaller, denser LDL. Insulin resistance means your tissues respond less effectively to insulin.

LDL4 is one slice of this distribution. Its concentration doesn't establish how many LDL particles you have in total, how much plaque is present, or whether you have insulin resistance.

Heart Attack and Stroke Risk

Genetic studies, population studies, and randomized trials establish that LDL particles cause atherosclerotic cardiovascular disease. Atherosclerosis is the buildup of plaque in artery walls. The evidence is much stronger for the cumulative burden of LDL and other ApoB-containing particles than for treating an individual LDL subclass.

In the Framingham Offspring Study, 3,066 middle-aged adults were followed for a median of 14.8 years. Total LDL particle number was more strongly associated with future cardiovascular disease than LDL cholesterol or non-HDL cholesterol. This study measured total LDL particles in plasma using a different NMR system; it did not validate serum LDL4 as a separate risk marker.

People with a low LDL particle count had fewer cardiovascular events (59 per 1,000 person-years) than people with low LDL cholesterol (81) or low non-HDL cholesterol (74). Low cholesterol didn't guarantee a low particle count. These were comparisons within the study population, not clinical definitions of a normal result.

A meta-analysis of NMR studies found that higher total LDL particle number was associated with greater cardiovascular risk, with a weaker association for small LDL particle number. These estimates concern total LDL and broader small-particle groups, not this individual subclass.

Other studies connect LDL size or density patterns with cardiovascular events, but their measurements and comparisons differ.

These findings support studying particle distributions, but none supplies a personal risk estimate for your serum LDL4 result. A low LDL4 count also cannot offset a high ApoB concentration, elevated lipoprotein(a), smoking, or a strong family history of early cardiovascular disease.

Insulin Resistance, Diabetes, and Fatty Liver

Smaller, denser LDL patterns often occur alongside high triglycerides, low HDL cholesterol, abdominal obesity, insulin resistance, type 2 diabetes, and fatty liver. These associations concern a broader lipoprotein pattern. An isolated LDL4 result cannot diagnose any of those conditions.

In the Brazilian ELSA-Brasil cohort, obesity was associated with more cholesterol in small dense LDL fractions. Diabetes and insulin resistance affected some of these relationships. That study separated serum particles by ultracentrifugation and measured their cholesterol content; its numbered subclasses are different from this NMR particle count.

A study of 128 Korean adults with obesity found that the triglyceride-glucose index was associated with smaller LDL size measured by gel electrophoresis. The index combines fasting triglycerides and glucose. It is a surrogate marker of insulin resistance, and this finding doesn't make LDL4 a diagnostic test for insulin resistance.

A systematic review of metabolic disease studies found that LDL cholesterol and particle-based measures often disagree. This is why ApoB can add useful information when triglycerides or blood sugar are elevated, even when LDL cholesterol looks unremarkable. It doesn't follow that each LDL subclass adds useful information beyond ApoB.

Where the Evidence Splits

The largest direct test of that question points against size. In 207,368 UK Biobank participants, measured with a different NMR platform, LDL particle size and size subclasses were no longer associated with coronary disease once the total count of ApoB-containing particles was accounted for. Lipoprotein(a) still added independent risk.

Other null findings line up. In the MESA cohort, small LDL particle number measured by NMR wasn't associated with coronary heart disease, and the National Lipid Association has concluded that LDL size adds little to prediction beyond LDL cholesterol. In a Korean community cohort, a nested comparison found that small dense LDL measured by gel electrophoresis did not independently predict cardiovascular disease, while diabetes did.

Differences in populations, methods, treatments, and statistical adjustment can change the apparent contribution of particle size. A negative finding doesn't prove that the particles are harmless, and a positive association doesn't establish that measuring or targeting LDL4 improves care. Once particle count is known, the best current evidence suggests size adds little.

When Results Can Be Misleading

• Different subclass boundaries: NMR, ion mobility, gel electrophoresis, and ultracentrifugation separate particles differently. Even different NMR systems use different models and subclass definitions. An LDL4 result from one system cannot be substituted for one from another.
• Estimated concentrations: NMR derives particle concentrations from overlapping magnetic signals. Calibration and the mathematical model affect how the signal is divided among neighboring subclasses, so small differences need cautious interpretation.
• Counts, cholesterol, and percentages: Particle concentration, cholesterol carried within a fraction, and the percentage of LDL assigned to that fraction describe different things. A cholesterol result cannot be converted into an LDL4 particle count using a fixed factor.
• Treatment-related redistribution: A smaller-particle percentage can stay the same or rise while the absolute burden of ApoB-containing particles falls. A percentage describes the mix of particles remaining in circulation.
• Specimen and handling: Collection tubes, storage conditions, and delays in processing can affect NMR profiles. Serum and plasma findings are biologically related, but results from different specimen protocols should not be treated as interchangeable.

A randomized trial of 579 high-risk adults already taking atorvastatin illustrates the percentage problem. Both adding ezetimibe and doubling the atorvastatin dose lowered LDL cholesterol, cholesterol in most LDL subfractions, and ApoB, but neither reduced the proportion of small dense LDL. The share of people with a small-particle pattern rose slightly. The study measured subclass cholesterol by ultracentrifugation, not LDL4 by NMR. It shows why a persistent or worsening dense pattern alone isn't evidence that treatment has failed.

Tracking Your Trend

Repeated LDL4 results can describe changes in particle distribution when the same method is used. There is no validated amount of change that establishes a reduction in heart attack or stroke risk. A personal baseline does not create a treatment target.

The interpretation depends on what happens to the broader particle burden. LDL4 can remain similar while ApoB falls, or its share can fall because another subclass increases. Total LDL particle number, ApoB, and the rest of your cardiovascular risk profile give those changes context.